FLUOXETINE HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H18F3NO.ClH
Molecular Weight	345.787
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2

InChI

InChIKey=GIYXAJPCNFJEHY-UHFFFAOYSA-N

InChI=1S/C17H18F3NO.ClH/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20;/h2-10,16,21H,11-12H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C17H18F3NO
Molecular Weight	309.3261
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf | https://www.drugs.com/fluoxetine.html

Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Fluoxetine is marketed under the trade names Prozac and Sarafem among others. It is also marketed for the treatment of premenstrual dysphoric disorder (Sarafem®, fluoxetine hydrochloride). PROZAC is a selective serotonin reuptake inhibitor indicated for: • Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years • Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years • Acute and maintenance treatment of Bulimia Nervosa in adult patients • Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients. Studies at clinically relevant doses in man have demonstrated that fluoxetine blocks the uptake of serotonin into human platelets. Studies in animals also suggest that fluoxetine is a much more potent uptake inhibitor of serotonin than of norepinephrine. Antagonism of muscarinic, histaminergic, and α1-adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin transporter 183 Target ID: CHEMBL228 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/9537821 \| https://www.ncbi.nlm.nih.gov/pubmed/19329313 \| https://www.ncbi.nlm.nih.gov/pubmed/17910821	Inhibitor 8504		10.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Major depressive disorder 179 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8583	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 1987
Obsessive-compulsive disorder 33 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8583	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 1987
Bulimia nervosa 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8583	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 1987
Panic disorder 24 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8583	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 1987

C_max

Value	Dose	Co-administered	Analyte	Population
22.56 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15968712	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13576.38 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16229112	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1101.46 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15968712	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
788626.72 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16229112	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
46.39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15968712	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
49.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16229112	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
5.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf			FLUOXETINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 substrate 1946	inhibitor 2438 substrate 1193	inhibitor 2507 substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Cav3.1 7 Cav3.2 12 Cav3.3 7 P-gp 1741 CYP2C19 2057 OCT1 620 OCT2 779	P-gp 2052 CYP1A2 1197 CYP2B6 776 CYP2C19 1119 CYP3A5 446	BCRP 101

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12649369/ \| https://pubmed.ncbi.nlm.nih.gov/21718296/ \| https://pubmed.ncbi.nlm.nih.gov/17962372/	moderate [IC50 31 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11876575/	moderate	norfluoxetine 2
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12649369/	moderate	norfluoxetine 2
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/	moderate		yes (co-administration study) Comment: addition of fluoxetine 20 mg/day to pre-existing risperidone therapy produced a mean 4- fold increase in plasma risperidone concentration, with some patients exhibiting an increase as large as 10-fold Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/
BCRP 985	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/31037729/	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/ \| https://pubmed.ncbi.nlm.nih.gov/27188854/ \| https://pubmed.ncbi.nlm.nih.gov/11876575/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	strong [IC50 1.05 uM]		yes (co-administration study) Comment: Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/ \| https://pubmed.ncbi.nlm.nih.gov/27188854/ \| https://pubmed.ncbi.nlm.nih.gov/11876575/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf
Cav3.1 7	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 14 uM]
Cav3.2 12	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 16 uM]
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/30361780/	yes [IC50 3.32 uM]
Cav3.3 7	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 30 uM]
Cav3.3 7	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 5 uM]	norfluoxetine 2
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24688079/ \| https://pubmed.ncbi.nlm.nih.gov/30361780/	yes [IC50 6.2 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9384467/	yes
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11270912/	yes		yes (co-administration study) Comment: Fluoxetine dosing inhibited CYP2C19 activity in both age groups, increasing the (S)- to (R)-mephenytoin ratio 3- to 4-fold Sources: https://pubmed.ncbi.nlm.nih.gov/11270912/

Drug as victim

Target	Modality	Activity
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21718296/ \| https://pubmed.ncbi.nlm.nih.gov/17962372/	minor
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/\| https://pubmed.ncbi.nlm.nih.gov/24464553/	yes [Ki 19 uM]
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/ \| https://pubmed.ncbi.nlm.nih.gov/16472103/ \| https://pubmed.ncbi.nlm.nih.gov/24464553/	yes
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP3A5 446	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/16967046/ \| https://pubmed.ncbi.nlm.nih.gov/11805215/
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/16967046/		norfluoxetine 2

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-034390	http://www.3bsc.com/index/pro_info.php?id=56297
AA Blocks	AA00I9Q5	http://www.aablocks.com/goods/Goods/detail?id=AA00I9Q5
Aaron Chemicals	AR00IAHX	http://www.aaronchem.com/54910-89-3
abcr GmbH	AB377357	http://www.abcr.com/shop/en/AB377357
Acadechem	ACDC-070879	http://acadechemical.com/product/11474
Achemo Scientific Limited	AC-14816	http://www.achemo.com/product_view.asp?ID=4706
Achemtek	0104-002971	http://www.achemtek.com/54910-89-3
AHH Chemical co.,ltd	MT-51855	http://www.ahhchemical.com/product/MT-51855.html
Alfa Chemistry	54910-89-3	https://www.alfa-chemistry.com/fluoxetine-cas-54910-89-3-item-292572.htm
Alinda	ALBB-025606	http://alinda.ru/finechem_en_.html?i=ALBB-025606
ApexBio Technology	A2436	http://www.apexbt.com/fluoxetine-hcl.html
AvaChem Scientific	2877B	http://www.avachem.com/productSearch.asp?2877B
BioChemPartner	BCP28440	http://www.biochempartner.com/54910-89-3-BCP28440
BLD Pharm	BD130609	http://www.bldpharm.com/products/54910-89-3.html
BOC Sciences	1173147-79-9	https://www.bocsci.com/fluoxetine-d5-solution-cas-1173147-79-9-item-185463.html
Chem Scene	CS-2861	http://www.chemscene.com/54910-89-3.html
Chemenu	CM118045	http://www.chemenu.com/products/CM118045
ChemMol	30103987	http://www.chemmol.com/chemmol/30103987.html
ChemMol	49402399	http://www.chemmol.com/chemmol/49402399.html
Chemspace	CSSB00000726877	https://chem-space.com/CSSB00000726877
Clearsynth	CS-O-01527	http://www.clearsynth.com/en/CSO01527.html
Debye Scientific	DB-015148	http://www.debyesci.com/cas_54910-89-3.html
Finetech	FT-0626489	http://www.finetechnology-ind.com/prod/detail/pub/54910-89-3.html
Glentham Life Sciences	GP3875	http://www.glentham.com/products/product/GP3875/
iChemical	EBD34153	http://www.ichemical.com/products/54910-89-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN00287054	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00287054
MedChem Express	HY-B0102	https://www.medchemexpress.com/fluoxetine.html
MuseChem	I004030	https://www.musechem.com/product/I004030.html
Smolecule	S590536	https://www.smolecule.com/products/s590536
THE BioTek	bt-305245	https://www.thebiotek.com/product/others/bt-305245
Yuhao Chemical	LT4939	http://www.chemyuhao.com/54910-89-3.html

PubMed

Title	Date	PubMed
The potentiating effect of sertraline and fluoxetine on amphetamine-induced locomotor activity is not mediated by serotonin.	1999 Apr	10367561
Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors.	1999 Jun	10394548
Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine.	2000	10665824
Antidepressant drugs appear to enhance cocaine-induced toxicity.	2000 Feb	10743914
Fluoxetine toxicity in a preterm infant.	2000 Oct-Nov	11076330
Evidence of early onset of antidepressant effect in randomized controlled trials.	2001	11229783
The effects of antidepressants on sexual functioning in depressed patients: a review.	2001	11229450
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.	2001	11229449
Effects of selective serotonin reuptake inhibitors on sexual function.	2001 Apr	11270925
Effect of chronic and acute administration of fluoxetine and its additive effect with morphine on the behavioural response in the formalin test in rats.	2001 Feb	11273019
Characterization of 5-HT receptors in the parasitic nematode, Ascaris suum.	2001 Feb	11272652
Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.	2001 Feb	11213850
Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers.	2001 Feb	11210405
Psychopharmacologic treatment of adolescent depression.	2001 Feb	11172238
Citalopram-induced bruxism.	2001 Feb	11157444
Fluoxetine and side effects in the geriatric population.	2001 Feb 1	11272295
Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania.	2001 Jan	11197585
Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal.	2001 Jan	11106878
Regulation of GFRalpha-1 and GFRalpha-2 mRNAs in rat brain by electroconvulsive seizure.	2001 Jan	11071708
Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study.	2001 Jan	10913689
Brain function in a patient with torture related post-traumatic stress disorder before and after fluoxetine treatment: a positron emission tomography provocation study.	2001 Jan 12	11121880
Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).	2001 Jan-Feb	11226552
Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.	2001 Mar	11181904
Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotonergic drugs.	2001 Mar 16	11251206

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Bulimia Immediate-release oral formulations: Recommended dose: 60 mg orally once a day Usual Adult Dose for Depression Immediate-release oral formulations: Initial dose: 20 mg orally once a day, increased after several weeks if insufficient clinical improvement is observed Maintenance dose: 20 to 60 mg orally per day Maximum dose: 80 mg orally per day Delayed release oral capsules: Initial dose: 90 mg orally once a week, commenced 7 days after the last daily dose of immediate-release fluoxetine 20 mg formulations. Usual Adult Dose for Obsessive Compulsive Disorder Immediate-release oral formulations: Initial dose: 20 mg orally once a day, increased after several weeks if insufficient clinical improvement is observed. Maintenance dose: 20 to 60 mg orally per day Maximum dose: 80 mg orally per day Usual Adult Dose for Panic Disorder Immediate-release oral formulations: Initial dose: 10 mg orally once a day, increased after one week to 20 mg orally once a day Maintenance dose: 20 to 60 mg orally per day Maximum dose: 60 mg orally per day

Route of Administration: Oral

In Vitro Use Guide

Caco-2 SERT was also shown to be a high affinity (Kt=0.216 uM) saturable, Na(+) -dependent transporter that was inhibited by fluoxetine (IC(50)=17.6 nM).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:56:37 GMT 2025` Edited by `admin` on `Mon Mar 31 17:56:37 GMT 2025`
Record UNII	I9W7N6B1KJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SYMBYAX COMPONENT FLUOXETINE HYDROCHLORIDE

Preferred Name

English

FLUOXETINE HYDROCHLORIDE

Official Name

English

LY-110140

Code

English

FLUOXETINE HYDROCHLORIDE [JAN]

Common Name

English

PROZAC

Brand Name

English

FONTEX

Brand Name

English

FLUNEURIN

Brand Name

English

LY110140

Code

English

FOXETIN

Brand Name

English

FLUOX-PUREN

Brand Name

English

Fluoxetine hydrochloride [WHO-DD]

Common Name

English

FLUOXETINE HYDROCHLORIDE [USP IMPURITY]

Common Name

English

FLUOXETINE HYDROCHLORIDE [MI]

Common Name

English

FLUOXETINE HYDROCHLORIDE [USAN]

Common Name

English

FLUXET

Brand Name

English

ADOFEN

Brand Name

English

FLUOXETINE HYDROCHLORIDE [HSDB]

Common Name

English

BENZENEPROPANAMINE, N-METHYL-.GAMMA.-(4-(TRIFLUOROMETHYL)PHENOXY)-, HYDROCHLORIDE (1:1)

Systematic Name

English

BENZENEPROPANAMINE, N-METHYL-.GAMMA.-(4-(TRIFLUOROMETHYL)PHENOXY)-, HYDROCHLORIDE, (±)-

Systematic Name

English

FLUOXETINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

RECONCILE

Brand Name

English

FLUOXETINE HYDROCHLORIDE [GREEN BOOK]

Common Name

English

FLUOXETINE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

SARAFEM

Brand Name

English

FLUOXETINE HYDROCHLORIDE [USP-RS]

Common Name

English

(±)-N-METHYL-3-PHENYL-3-((.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-P-TOLYL)OXY)PROPYLAMINE, HYDROCHLORIDE

Common Name

English

FLUCTIN

Brand Name

English

LOVAN

Brand Name

English

FLUOXETINE (AS HYDROCHLORIDE)

Common Name

English

FLUSOL

Brand Name

English

FLUOXETINE HYDROCHLORIDE [VANDF]

Common Name

English

FLUOXETINE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

FLUOXEREN

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C94725